Ingen Enjoys Large Target Market with New Adult Nasal Cannula

Oxyview adult nasal cannula is used in the aviation and hospital industries as well as by in-home oxygen support patients

Yucaipa, CA, January 5, 2010ďż˝Ingen Technologies, Inc, a leading manufacturer of medical devices for respiratory treatment, announced today that their adult nasal cannula is available to a market that includes hundreds of millions of patients worldwide. With such a large demand for reliable, convenient oxygen cannulas, Ingen expects to see their market share grow in 2010 and the years to come.

In the United States alone, there are 23 million patients who suffer from chronic obstructive pulmonary disease (COPD). Worldwide, the number of individuals with COPD is 600 million and growing by the year. Those with COPD use nasal cannulas, and the average person uses about 2-3 adult nasal cannulas each month to prevent bacteria buildup within the device. The in-home oxygen support patient market alone accounts for hundreds of millions of dollars spent each year on oxygen cannulas, but Ingen wishes to enter new markets as well.

In 2010, the adult nasal cannula manufacturer plans to aggressively market its medical devices to hospitals. Because of Oxyview nasal cannula's convenience and reliability, hospitals are the ideal market for this device. Oxyview is said to provide additional assurance of oxygen flow, and it's easy to install on all liquid and gas O2 systems. But Ingen's bold plans for growth don't end here. The company also hopes to work with distributors to make the Oxyview adult nasal cannula available worldwide, particularly in the developing markets of Asia, Europe, and Latin America. Recently, at the MEDICA convention in Germany, Ingen's showcase of Oxyview earned the company attention from multiple distributors that were on hand for the event.

In addition to the adult nasal cannula, Ingen also offers oxygen cannulas for children and infants. For more information, please visit www.Ingen-Tech.com.